CAR T-cell treatment during the COVID-19 pandemic: Management strategies and challenges - 19/08/20
Abstract |
The pandemic of coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is spreading rapidly across the world. Currently, the COVID-19 pandemic is affecting the continuity of essential routine healthcare services and procedures, including chimeric antigen receptor T-cell (CAR-T) therapy, a life-saving option for patients with relapsed/refractory (R/R) hematologic malignancies. Due to the rapid disease progression of hematological malignancies, there is an urgent need to manufacture and utilize CAR T-cells. However, CAR-T treatment has become extraordinarily challenging during this COVID-19 pandemic. Thus, many medical and technical factors must now be taken into consideration before, during, and after CAR-T therapy. The purpose of this review is to provide brief suggestions for rational decision-making strategies in evaluating and selecting CAR T-cell treatment and appropriate CAR T-cell products, and protective strategies for medical staff and patients to prevent infection in the midst of the current COVID-19 pandemic.
Le texte complet de cet article est disponible en PDF.Keywords : Chimeric antigen receptor T-cells, COVID-19, Relapsed/refractory hematological malignancies, Immunocompromised, Cytokine release syndrome
Plan
Vol 68 - N° 3
P. 111-118 - août 2020 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.